Trial Profile
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Ebola virus vaccine (Primary) ; VRC-EBOADV018-00-VP (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions; Pharmacodynamics
- 05 May 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 05 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.